Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers

PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, lead to significant tumor regressions in 10% to 15% of non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. However, 30% to 40% of NSCLC patients, majority of whom are EGFR wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yonesaka, Kimio, Zejnullahu, Kreshnik, Lindeman, Neal, Homes, Alison J., Jackman, David M., Zhao, Feng, Rogers, Andrew M., Johnson, Bruce E., Jänne, Pasi A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227691/
https://ncbi.nlm.nih.gov/pubmed/18980991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0957
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados